Atrin logo sent
Atrin 20logo 20white 20final

Atrin pharmaceuticals

Targeted small molecule therapeutics for treating cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location Doylestown, PA, US
  • Currency USD
  • Founded January 2011
  • Employees 10
  • Incorporation Type LLC
  • Website atrinpharma.com

Company Summary

Atrin Pharmaceuticals is an emerging biotech with soon to be clinic ready and current deep preclinical programs generated from a unique chemistry platform and leading science team in the field of ATR mediated DNA Damage and Response (DDR) originally from University of Pennsylvania squarely centered in the field of synthetic lethality, cell cycle regulation and DDR.

Team

  • Default avatar
    Oren Gilad
    CEO

    Dr. Gilad has extensive leadership experience across all phases of drug development. He has an accomplished track record leading Atrin from inception to pre-clinical and moving into the clinical stage. Prior to founding Atrin in 2011, Dr. Gilad had a 13-year academic career, where he has authored numerous high impact scientific articles. This breakthrough research was conducted at the University of Pennsylvania.

  • Richard Fitzgerald has over 35 years of progressive finance, capital markets, and operations leadership experience supporting both public and private companies, predominately within the life sciences industry. He has a proven track record of delivering positive results and driving shareholder value. Mr. Fitzgerald previously served as CFO at Sesen Bio (Nasdaq: SESN), PAVmed (Nasdaq: PAVM), during his tenure PAVmed successfully completed its IPO

  • Default avatar
    Zeev Weiss, CPA, B.Sc
    CBO

    Zeev has over 20 years of broad and extensive biopharmaceuticals industry experience in strategic, operational, and corporate development in the emerging and established healthcare industry. Until 2017, Zeev served as the CEO Intec (NASDAQ: NTEC) leading successful IPO on NASDAQ.
    Prior to Intec, Zeev was Head of Life Sciences Strategic Consulting at PwC, Israel. At PwC, Zeev led corporate developments, BD, strategic planning and corporate finance

  • Default avatar
    Michel Afargan, Ph.D
    Head Pharmacology Development

    Dr. Afargan has over 25 years of experience as a Senior Executive in Drug Discovery and Development. Dr. Afargan is co-author of 7 INDs, 2 IDEs and 2 505(B)2. Since 2012. He is the innovator of the novel peptide-based drug Somatoprim® for the treatment of metabolic disorders and adenocarcinomas, and inventor of a series of issued and pending patents in innovative drug delivery systems.

  • Default avatar
    Joseph Vacca, Ph.D.
    Medicinal Chemistry

    Dr. Vacca has over 35 years of experience as a Senior Executive in Drug Discovery and Development, including over 30 years at Merck & Co., where he contributed to the discovery of thrombin, BACE, and HCV inhibitors; and the discovery and development of HIV integrase inhibitors. His work on the HIV-1 protease project led to the discovery of Merck’s CRIXIVAN. Dr. Vacca named to the American Chemical Society Medicinal Chemistry Hall of Fame.

Advisors

  • Default avatar
    Bernard Rudnick
    Unconfirmed
    Default avatar
    Rifat Pamucku, M.D.
    Unconfirmed
  • Default avatar
    Dr. Jay Rosan
    Unconfirmed
    Default avatar
    Marc Duey, M.Sc, MBA
    Unconfirmed
  • Default avatar
    Renold Capocasale
    Unconfirmed

Previous Investors

  • Default avatar
    This information is confidential
    Unconfirmed